OS Therapies Incorporated (OSTX)
- Previous Close
2.2000 - Open
2.1500 - Bid 2.2700 x 1000
- Ask 2.4000 x 1300
- Day's Range
2.0600 - 2.4900 - 52 Week Range
1.1200 - 7.0000 - Volume
394,511 - Avg. Volume
858,990 - Market Cap (intraday)
50.693M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-0.9400 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
13.50
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Grasonville, Maryland.
ostherapies.comRecent News: OSTX
View More
Performance Overview: OSTX
Trailing total returns as of 5/6/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: OSTX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: OSTX
View MoreValuation Measures
Market Cap
50.69M
Enterprise Value
67.30M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-134.41%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-10.89M
Diluted EPS (ttm)
-0.9400
Balance Sheet and Cash Flow
Total Cash (mrq)
5.53M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-8.54M